# Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies

> **NCT00679133** · PHASE1 · COMPLETED · sponsor: **Mirati Therapeutics Inc.** · enrollment: 47 (actual)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** MGCD265

## Key facts

- **NCT ID:** NCT00679133
- **Lead sponsor:** Mirati Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2015-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00679133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00679133, "Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00679133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*